A Proof of Concept Study of Pradigastat in Patients With Functional Constipation

Functional Constipation Clinical Trial

Official title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Proof of Concept Study to Assess the Efficacy, Safety and Tolerability of Pradigastat in Patients With Functional Constipation

Status Completed

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy, safety, and tolerability of pradigastat 20 and 40 mg as compared to placebo in patients with Functional Constipation.

Clinical Trial Description

This multicenter, randomized, placebo-controlled, double-blind study is designed to demonstrate the efficacy, safety and tolerability of pradigastat relative to placebo across 2 doses (20 and 40 mg) for up to 6 weeks (4-week treatment, 2-week Follow-up) in patients with Functional Constipation.

The primary endpoint is the change from baseline in the number of weekly spontaneous bowel movement (SBM), the key secondary endpoint is the change from baseline in the number of weekly complete spontaneous bowel movement (CSBM).An SBM is defined as a stool not induced by rescue medication, whereas a CSBM is defined as an SBM associated with a sensation of complete evacuation.

Summary of Protocol Amendments:

• Original Protocol: 06 January 2020

• Amendment 1: 30 July 2020 (Reason: To respond Health Authority requests)

• Amendment 2: 05 March 2021 (Reason: Sponsor decided to amend the protocol. Key changes:

inclusion/exclusion criteria, criteria for Discountinuation from study/Discontinuation from Study Medication, adding the instruction for evaluating and managing diarrhea AEs. ) ;

Related Conditions & MeSH terms

• Constipation
• Functional Constipation

• NCT number: NCT04620161
• Study type: Interventional
• Source: Anji Pharma
• Status: Completed
• Phase: Phase 2
• Start date: September 22, 2020
• Completion date: June 3, 2022